Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - Mersana Therapeutics, Inc. | exhibit31210kfy2020q4.htm |
| EX-31.1 - EX-31.1 - Mersana Therapeutics, Inc. | exhibit31110kfy2020q4.htm |
| EX-23.1 - EX-23.1 - Mersana Therapeutics, Inc. | exhibit23110kfy2020q4.htm |
| EX-21.1 - EX-21.1 - Mersana Therapeutics, Inc. | exhibit21110kfy2020q4.htm |
| 10-K - 10-K - Mersana Therapeutics, Inc. | mrsn-20201231.htm |
Exhibit 32.1
CERTIFICATIONS OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT
TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with this Annual Report on Form 10-K of Mersana Therapeutics, Inc. (the “Company”) for the year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the company, hereby certifies, pursuant to Section 1350 of Chapter 63 of Title 18, United States Code, that to the best of her or his knowledge:
(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Date: February 26, 2021 | By: | /s/ Anna Protopapas | |||||||||
| Anna Protopapas President and Chief Executive Officer (Principal Executive Officer) | |||||||||||
| Date: February 26, 2021 | By: | /s/ Brian DeSchuytner | |||||||||
| Brian DeSchuytner Senior Vice President, Finance & Product Strategy (Principal Financial Officer) | |||||||||||